Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)
~13 mi.
(Balashikha,
Russia,
+93 more cities)
Moscow Regional Oncological Dispensary ( Site 0812)
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
~13 mi.
(Balashikha,
Russia,
+122 more cities)
Moscow Regional Oncological Dispensary-Oncology (thoracic surgery) Department №1 ( Site 1815)
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
~20 mi.
(Moscow,
Russia,
+192 more cities)
Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
~20 mi.
(Moscow,
Russia,
+144 more cities)
Moscow Oncological Clinical Dispensary #1 ( Site 2619),
+1 more
facility
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
~20 mi.
(Moscow,
Russia,
+176 more cities)
FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 2634)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
~20 mi.
(Moscow,
Russia,
+89 more cities)
Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 1901),
+2 more
facilities
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
~20 mi.
(Moscow,
Russia,
+226 more cities)
Central Clinical Hospital with Polyclinic ( Site 0562),
+1 more
facility
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
~20 mi.
(Moscow,
Russia,
+147 more cities)
MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 0722)
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
~20 mi.
(Moscow,
Russia,
+199 more cities)
Blokhin National Medical Oncology ( Site 0645),
+2 more
facilities
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
~20 mi.
(Moscow,
Russia,
+159 more cities)
FSBI ""United Hospital with Polyclinic"" of the Administrative Department of the President of the Ru,
+1 more
facility